RxDoctor Payments Data

Jenna Luczka, PA

Family Medicine · Smithfield, PANPI 1972147874

Payments from drug & device makers

$8,600in general payments, 2019–2025

Across 547 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$907
  • GSK$856
  • Boehringer Ingelheim$856
  • AbbVie$647
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,600100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,600 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,589
Medicare patients
193
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$128,745
EliquisApixaban111$86,335
MounjaroTirzepatide38$51,391
TrulicityDulaglutide45$48,715
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$39,524
JardianceEmpagliflozin39$38,635
FarxigaDapagliflozin Propanediol30$33,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$26,529
Tresiba Flextouch U-200Insulin Degludec14$11,984
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,789
Xultophy 100-3.6Insulin Degludec/Liraglutide14$10,714
Synjardy XrEmpagliflozin/Metformin Hcl15$9,820
Spiriva RespimatTiotropium Bromide17$8,879
MyrbetriqMirabegron13$8,595
Humalog Kwikpen U-100Insulin Lispro21$4,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$1,377$139,45993 claims
Lilly USA, LLCMounjaro, Trulicity$1,059$100,10683 claims
PfizerEliquis$322$86,335111 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$856$57,33471 claims
AstraZenecaFarxiga, Breztri Aerosphere$907$44,38341 claims
GSKTrelegy Ellipta$856$26,52923 claims
Astellas Pharma US IncMyrbetriq$34$8,59513 claims
Almatica Pharma LLCSertraline Hcl$14$1,764109 claims
AbbVieSynthroid$647$90926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Smithfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →